Drugs and Polymers for Delivery Systems in OA Joints: Clinical Needs and Opportunities

M. Janssen, G. Mihov, T. Welting, J. Thies, P. Emans*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Osteoarthritis (OA) is a big burden of disease worldwide and one of the most common causes of disability in the adult population. Currently applied therapies consist of physical therapy, oral medication, intra-articular injections, and surgical interventions, with the main goal being to reduce pain and improve function and quality of life. Intra-articular (IA) administration of drugs has potential benefits in OA treatment because it minimizes systemic bioavailability and side effects associated with oral administration of drugs without compromising the therapeutic effect in the joint. However, IA drug residence time is short and there is a clinical need for a vehicle that is able to provide a sustained release long enough for IA therapy to fulfill its promise. This review summarizes the use of different polymeric systems and the incorporated drugs for IA drug delivery in the osteoarthritic joint with a primary focus on clinical needs and opportunities.

Original languageEnglish
Pages (from-to)799-819
Number of pages21
JournalPolymers
Volume6
Issue number3
DOIs
Publication statusPublished - Mar 2014

Keywords

  • osteoarthritis
  • drug delivery systems
  • DMOAD
  • LOADED PLGA MICROSPHERES
  • IN-VIVO EVALUATION
  • INTRAARTICULAR DELIVERY
  • ALBUMIN MICROSPHERES
  • KNEE OSTEOARTHRITIS
  • SUSTAINED-RELEASE
  • PROTEIN DELIVERY
  • METALLOPROTEINASE INHIBITOR
  • BIODEGRADABLE MICROSPHERES
  • CHITOSAN MICROSPHERES

Cite this